Stryker Corporation (SYK) Stock Price Today
Aura AI Summary
Key Stats
- $113.02BMarket Cap
- 3,377,110Volume
- HealthSector
- $388.3552W High
- $269.7552W Low
- 19 DaysTypical Hold Time
- $124.49BEnterprise Value
- 1.19%Div Yield
- -Trading Activity
Track Stryker Corporation (SYK) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Stryker Corporation has traded between a low of $269.75 and a high of $388.35, highlighting its annual price range. Buy and sell Stryker Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Most Recent News
Kingfisher Mining raises $2.25M to boost Copper Blow copper-gold exploration near Broken Hill.
Kingfisher Mining secured $2.25 million through a share placement at a 5.6% premium to fund expanded drilling and exploration at its Copper Blow Project near Broken Hill. Recent drilling showed promising copper-gold grades, with significant untested ...

Disc Medicine to webcast APOLLO Phase 3 trial results of bitopertin for erythropoietic protoporphyria
Disc Medicine announced a webcast on October 19, 2026, to discuss topline results from its APOLLO Phase 3 trial of bitopertin, an investigational oral drug for erythropoietic protoporphyria (EPP). Bitopertin targets glycine transporter 1 to modulate ...

Actinogen Medical nears key Alzheimer's trial results with strong cash position of A$21.9M.
Actinogen Medical completed the main phase of its XanaMIA Phase 2b/3 Alzheimer's trial, with topline results expected in November. The trial tests Xanamem 10 mg daily in mild to moderate Alzheimer's patients, focusing on cognitive outcomes. The compa...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.